文献速递肝病消化道肿瘤与早癌

Siglec-9/Siglec-9L相互作用增强预示HCC预后不良并可靶向用于免疫治疗

Increased Siglec-9/Siglec-9L interactions on NK cells predict poor HCC prognosis and present a targetable checkpoint for immunotherapy.
PubMed 文献 · J Hepatol · 2024-02-07

该研究通过多重免疫荧光分析HCC组织中Siglec-7、Siglec-9及其配体的表达模式,发现肿瘤浸润NK细胞上Siglec-9表达显著上调且与患者生存期缩短相关,Siglec-9L+细胞邻近Siglec-9+NK细胞的数量增加也与肿瘤复发和生存期缩短相关。研究通过对接虚拟筛选结合生物层干涉技术鉴定出小分子Siglec-9抑制剂MTX-3937,可抑制Siglec-9及下游SHP1/SHP2磷酸化,增强NK细胞功能,在体外和肝癌荷瘤NCG小鼠中显示治疗潜力。

要点

  • 肿瘤浸润NK细胞上Siglec-9表达上调与HCC患者生存期缩短显著相关。
  • Siglec-9L+细胞邻近Siglec-9+NK细胞数量增加与HCC复发和生存期缩短相关。
  • 小分子抑制剂MTX-3937靶向Siglec-9增强NK细胞毒性并抑制小鼠肝癌生长。

核心结论

  • Siglec-9/Siglec-9L相互作用是HCC的潜在治疗靶点,靶向Siglec-9的小分子抑制剂MTX-3937可增强NK细胞介导的HCC免疫监视。

研究设计与样本

  • 研究采用多重免疫荧光染色分析HCC组织中Siglec-7、Siglec-9及其配体的表达模式,并通过对接虚拟筛选联合生物层干涉技术鉴定小分子Siglec-9抑制剂,在体外和肝癌荷瘤NCG小鼠中评估治疗潜力。

主要发现

  • 肿瘤浸润NK细胞上Siglec-9表达而非Siglec-7显著上调,与HCC患者生存期缩短显著相关。
  • HCC组织中邻近Siglec-9+NK细胞的Siglec-9L+细胞数量增加,与肿瘤复发和生存期缩短相关。
  • MTX-3937抑制Siglec-9及下游SHP1和SHP2磷酸化,改善NK细胞功能,增强人外周血和肿瘤浸润NK细胞的细胞毒性。
  • 转输MTX-3937处理的NK92细胞大幅抑制NCG小鼠肝癌异种移植瘤生长。

临床怎么用

  • 靶向NK细胞Siglec-9的小分子抑制剂MTX-3937可作为增强HCC免疫治疗疗效的新策略,值得进一步临床研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Natural killer (NK) cell-based anti-hepatocellular carcinoma (HCC) therapy is an increasingly attractive approach that warrants further study. Siglec-9 interacts with its ligand (Siglec-9L) and restrains NK cell functions, suggesting it is a potential therapeutic target. However, in situ Siglec-9/Siglec-9L interactions in HCC have not been reported, and a relevant interventional strategy is lacking. Herein, we aim to illustrate Siglec-9/Siglec-9L-mediated cell sociology and identify small-molecule inhibitors targeting Siglec-9 that could improve the efficacy of NK cell-based immunotherapy for HCC. METHODS: Multiplexed immunofluorescence staining was performed to analyze the expression pattern of Siglec-7, -9 and their ligands in HCC tissues. Then we conducted docking-based virtual screening combined with bio-layer interferometry assays to identify a potent small-molecule Siglec-9 inhibitor. The therapeutic potential was further evaluated in vitro and in hepatoma-bearing NCG mice. RESULTS: Siglec-9 expression, rather than Siglec-7, was markedly upregulated on tumor-infiltrating NK cells, which correlated significantly with reduced survival of patients with HCC. Moreover, the number of Siglec-9L+ cells neighboring Siglec-9+ NK cells was increased in HCC tissues and was also associated with tumor recurrence and reduced survival, further suggesting that Siglec-9/Siglec-9L interactions are a potential therapeutic target in HCC. In addition, we identified a small-molecule Siglec-9 inhibitor MTX-3937 which inhibited phosphorylation of Siglec-9 and downstream SHP1 and SHP2. Accordingly, MTX-3937 led to considerable improvement in NK cell function. Notably, MTX-3937 enhanced cytotoxicity of both human peripheral and tumor-infiltrating NK cells. Furthermore, transfer of MTX-3937-treated NK92 cells greatly suppressed the growth of hepatoma xenografts in NCG mice. CONCLUSIONS: Our study provides the rationale for HCC treatment by targeting Siglec-9 on NK cells and identifies a promising small-molecule inhibitor against Siglec-9 that enhances NK cell-mediated HCC surveillance. IMPACT AND IMPLICATIONS: Herein, we found that Siglec-9 expression is markedly upregulated on tumor-infiltrating natural killer (TINK) cells and correlates with reduced survival in patients with hepatocellular carcinoma (HCC). Moreover, the number of Siglec-9L+ cells neighboring Siglec-9+ NK cells was increased in HCC tissues and was also associated with tumor recurrence and reduced survival. More importantly, we identified a small-molecule inhibitor targeting Siglec-9 that augments NK cell functions, revealing a novel immunotherapy strategy for liver cancer that warrants further clinical investigation.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Xiao R, Tian Y, Zhang J, et al. Increased Siglec-9/Siglec-9L interactions on NK cells predict poor HCC prognosis and present a targetable checkpoint for immunotherapy. J Hepatol. 2024. PMID: 38331327. doi:10.1016/j.jhep.2024.01.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。